Liver cancer: adjuvant TACE extends survival in low-risk patients

  • Cancer Manag Res

  • de Jim Kling
  • Univadis Clinical Summaries
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • Postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) was associated with extended PFS and OS in low-risk patients with hepatocellular carcinoma (HCC).

Why this matters

  • Data on PA-TACE survival benefit have been largely limited to intermediate- and advanced-stage HCC.

Study design

  • Monocentric Chinese study of 180 patients with HCC who achieved R0 status with hepatectomy; 102 underwent adjuvant PA-TACE and 78 did not (controls).
  • Funding: None disclosed.

Key results

  • Median follow-up, 56 months.
  • Compared with control patients, PA-TRACE improved median OS (90.7 vs 54.4 months; P<.001 and vs months p>
  • PA-TACE vs control, low-risk group:
    • Noninvading: OS, 90.1 vs 52.8 months (P<.001 pfs vs months>
    • Nonportal vein invasion: OS, 91.3 vs 52.2 months (P<.001 pfs vs months>
    • Child-Pugh A: OS, 91.3 vs 65.8 months (P<.001 pfs vs months>
    • Single-lesion: OS, 91.4 vs 47.2 months (P<.001 pfs vs months>
  • PA-TACE yielded no significant PFS (P=.629) or OS (P=.254) benefit among 11 high-risk patients (lesions >3 cm, multiple lesions, or portal branch/surrounding tissues invasion) and among female patients (P=.121; P=.104).
  • PA-TACE adverse events included fever, pain, nausea, and fatigue; most were grade 1/2.

Limitations

  • Retrospective design.